Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
- Discuss the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
- Recall second-line therapies used in non-small-cell lung cancer
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.